betamethasone-17,21-dipropionate and Disease Exacerbation

betamethasone-17,21-dipropionate has been researched along with Disease Exacerbation in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Duvetorp, A; Engerstedt Mattsson, E; Levin, LÅ; Ryttig, L	1
Kircik, LH	1

Trials

1 trial(s) available for betamethasone-17,21-dipropionate and Disease Exacerbation

Article	Year
Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:8 Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Calcitriol; Contraceptives, Oral, Combined; Dermatologic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Pilot Projects; Psoriasis; Receptors, Tumor Necrosis Factor; Sample Size; Treatment Outcome	2011

Article

Year

Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.

Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:8

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Calcitriol; Contraceptives, Oral, Combined; Dermatologic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Pilot Projects; Psoriasis; Receptors, Tumor Necrosis Factor; Sample Size; Treatment Outcome

2011

Other Studies

1 other study(ies) available for betamethasone-17,21-dipropionate and Disease Exacerbation

Article	Year
A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden. Acta dermato-venereologica, 2019, Apr-01, Volume: 99, Issue:4 Topics: Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Clinical Decision-Making; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Dermatologic Agents; Disease Progression; Drug Compounding; Drug Costs; Glucocorticoids; Humans; Models, Economic; Office Visits; Ointments; Phototherapy; Psoriasis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sweden; Time Factors; Treatment Outcome	2019

Article

Year

A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.

Acta dermato-venereologica, 2019, Apr-01, Volume: 99, Issue:4

Topics: Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Clinical Decision-Making; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Dermatologic Agents; Disease Progression; Drug Compounding; Drug Costs; Glucocorticoids; Humans; Models, Economic; Office Visits; Ointments; Phototherapy; Psoriasis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sweden; Time Factors; Treatment Outcome

2019